HB 775 modifies Louisiana law to expand when minors can consent to medical care without parental permission. It allows minors aged 13-17 to consent to treatment for pregnancy, sexually transmitted infections, substance misuse, and certain emergencies (like abuse or neglect), while requiring parental access to medical records. The bill also prohibits schools or facilities from providing preventive care to minors without parental consent and shields healthcare providers from liability for following these rules. It repeals prior provisions that permitted broader minor consent or school-based care without parental involvement. This directly affects minors, parents/guardians, healthcare providers, and schools in Louisiana.
HB 944 creates the Louisiana Women's Health Consortium within the Louisiana Department of Health to address women's health needs across the state. The consortium will include 15 voting members representing health institutions (like Tulane School of Medicine and Woman's Hospital), government agencies (such as the surgeon general's office), and community stakeholders, plus nonvoting members from additional health organizations. Its core duties include developing a state funding plan for women's health initiatives, creating a comprehensive Women's Health Agenda focusing on issues like perimenopause and menopause, and identifying systemic barriers to care. The consortium must hold quarterly public meetings, submit an annual report to the legislature, and coordinate an online resource hub for evidence-based women's health information.
HB 302 prohibits new permits for businesses to sell vapor products within 300 feet of school property lines. It directly affects businesses seeking to open or operate vapor product sales near schools, requiring them to be at least 300 feet away. The bill specifies measurement can be either by sidewalk path (in areas with sidewalks) or straight line, with the straight-line method applying only to new permits issued after its adoption. This policy change restricts where new vapor product businesses can operate near schools but does not affect existing businesses.
This bill requires the Louisiana Department of Health to equalize Medicaid reimbursement rates between independent rural health clinics and provider-based rural health clinics. It mandates that independent clinics receive the same payment rates as provider-based clinics to ensure fair compensation for services provided in rural areas. The Department of Health must prepare necessary state plan amendments or adopt rules to implement this change, with implementation required by October 1, 2026. This policy directly affects rural health clinics in Louisiana that participate in the Medicaid program.
This bill removes the legal provision that set a termination date for the Louisiana Behavior Analyst Board, allowing the regulatory body to continue operating. By repealing the specific statute that established the board's expiration, the legislation ensures the board remains active for overseeing behavior analysts in the state. The change directly affects the board's ability to regulate professionals and maintain oversight without a fixed end date. No new powers or requirements are added; the bill simply eliminates the existing deadline for the board's existence.
HB 895 requires Louisiana hospitals and healthcare providers to offer sexual assault survivors specific medical treatments without undue delay. It mandates that providers make emergency contraception available and provide at least a three-day supply of HIV/STI prevention medication when medically needed, alongside private examinations adapted to each survivor's needs. The bill also requires hospitals to offer a survivor advocate (with confidential communications) during forensic exams, with the survivor's consent. This directly affects sexual assault survivors receiving emergency medical care in Louisiana hospitals.
HB 291 prevents health insurers in Louisiana from penalizing hospitals or clinics (participating healthcare facilities) solely because another provider at that facility - like a doctor or specialist - is dropped from the insurer's network. The bill directly affects healthcare facilities that coordinate patient care with multiple providers, ensuring they won’t face payment cuts or contract terminations due to a partner provider’s network status. Key provisions ban insurers from reducing payments or ending agreements with facilities based on another provider’s network exclusion, and require that any contract clauses attempting to override this rule are void. This policy change aims to stabilize provider relationships and care continuity for patients.
HB 823 establishes a pilot program in Orleans Parish that offers homeless individuals facing criminal charges an alternative to court proceedings. Instead of traditional sentencing, eligible defendants can participate in a diversion program providing housing assistance, mental health services, job training, and substance abuse treatment. If participants successfully complete the program’s requirements, the criminal charges are dismissed without a conviction. The program requires annual evaluations and reporting to the Louisiana Supreme Court, aiming to reduce recidivism, court workload, and prison overcrowding while addressing homelessness through community partnerships.
HB 766 requires health insurers in Louisiana to cover orally administered anti-cancer medications on the same terms as intravenously administered ones. It prohibits insurers from imposing higher copays, deductibles, or prior authorizations for oral medications compared to IV treatments, and bans programs that ignore drug discounts (like "accumulator" programs). The bill caps out-of-pocket costs for oral anti-cancer drugs at $100 per prescription and ensures cost-sharing counts toward annual out-of-pocket maximums. It applies to most health plans but excludes limited-benefit policies, high-deductible plans with HSAs, and self-funded ERISA plans. This directly affects cancer patients and insurers by reducing financial barriers to oral medication access.
HCR 120 establishes the PACE Task Force to study GLP-1 medications, which are drugs used for diabetes and weight loss that have seen a massive increase in demand and cost in Louisiana. This concurrent resolution directs the task force to investigate how these drugs affect insurance premiums, accessibility for different income groups, and the long-term financial impact on both public and private insurers. The group will consist of representatives from state agencies, health plans, and medical providers, who will meet to analyze pricing differences between diabetes and weight loss uses before submitting their findings to the legislature by February 2027.
